Am J Transplant, Volume 18, Suppl 3 Archives - Page 29 of 211 - ATC Abstracts

2018 American Transplant Congress
Memory T Cell Dysfunction after Pregnancy Alloimmunization Prolongs Transplant Survival
P. Porrett,¹ J. Cohen,² R. Xu,¹ E. Lewis,³ M. Elovitz,³ E. Wherry,⁴ D. Sawinski.²
¹Surgery, University of Pennsylvania, Philadelphia, PA; ²Medicine, University of Pennsylvania, Philadelphia, PA; ³OBGyn, University of Pennsylvania, Philadelphia, PA; ⁴Microbiology, University of Pennsylvania, Philadelphia, PA.
Background Pregnancy alloimmunization can preclude donor compatibility and may diminish transplant lifespan. While these consequences may be attributed to immunologic memory responses that endanger an…
2018 American Transplant Congress
CD4⁺ T Cells Are Key Barriers to Tolerance Resistance to Islet Allografts in Autoimmune NOD Mice
A. Burrack,¹ K. Beard,² M. Coulombe,² R. Gill.²
¹Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, MN; ²Surgery, University of Colorado Denver, Aurora, CO.
Pancreatic islet allografts are effective for restoring euglycemia in type 1 diabetics (T1D) but are vulnerable to rejection by autoreactive (islet-specific) and/or conventional alloreactive T…
2018 American Transplant Congress
Histone Deacetylase Inhibition Mitigates Limb Ischemia Reperfusion Injury
S. Concors,¹ D. Aufhauser,¹ D. Murken,¹ Z. Wang,¹ G. Ge,¹ T. Bhatti,⁴ W. Hancock,^3,4 M. Levine.^1,2
¹Surgery, University of Pennsylvania, Philadelphia, PA; ²Surgery, Children's Hospital of Philadelphia, Philadelphia, PA; ³Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA; ⁴Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA.
Introduction: Vascular composite allotransplantation (VCA) of the limb involves cold and warm ischemia, further limiting organ availability beyond the constraints of blood type, HLA compatibility,…
2018 American Transplant Congress
Novel Function of TIE2 in Immunoregulation
C. Ghosh, T. Agur, A-.L. Mak, S. Pal, J. Wedel, B. David.
Transplant Research Program, Boston Children's Hospital, Boston, MA.
The immunogenicity of graft microvascular endothelial cells (ECs) has immense biological significance in the modulation of the local intragraft microenvironment. EC may either support Teffector…
2018 American Transplant Congress
Can Immunosuppression Maintenance after Renal Allograft Failure Prevent Further Sensitization?
A. Mena-Gutierrez, K. Alquadan, A. Santos, K. Womer, M. Casey.
University of Florida, Gainesville.
After renal graft failure, retransplantation(ReTx) becomes more difficult due to sensitization to alloantigens. In 2013, our center opened a specialty clinic to maintain immunosuppression(IS) after…
2018 American Transplant Congress
Pre-Donation eGFR, Early Post-Donation eGFR, and Subsequent ESRD Risk in Living Kidney Donors
A. Massie,¹ L. Fahmy,¹ M. Henderson,¹ A. Thomas,¹ J. Snyder,² D. Segev.¹
¹Johns Hopkins, Baltimore; ²SRTR, Minneapolis.
The relationship between predonation eGFR and long-term risk of postdonation ESRD has not been characterized. Moreover, while transplant centers are required to collect postdonation serum…
2018 American Transplant Congress
Accepting a DCD Liver May Improve Patient Survival Compared to Waiting for a Non-DCD Liver
A. Wey,¹ N. Salkowski,¹ J. Lake,² W. Kim,³ B. Kasiske,¹ A. Israni,¹ J. Snyder.¹
¹Scientific Registry of Transplant Recipients, Minneapolis; ²Univ of Minnesota, Minneapolis; ³Stanford University, Palo Alto.
Only ~50% of liver candidates undergo deceased donor transplant; 17% die on the waiting list and 20% are removed from the list as too sick…
2018 American Transplant Congress
Cost Effectiveness of Hepatitis C Positive Donor Kidney Transplantation for Hepatitis C Negative Recipients with Concomitant Direct-Acting Anti-Viral Therapy
G. Gupta, Y. Zhang, H. Kale, N. Carroll, R. Sterling.
Virginia Commonwealth University, Richmond.
Background: The development of direct acting antiviral (DAA) therapy for hepatitis C virus (HCV) could allow for safe and effective treatment following renal transplantation (RT).…
2018 American Transplant Congress
Using the Explore Transplant Ontario Program to Increase Transplant Knowledge and Readiness among Patients on Maintenance Dialysis
D. Belenko,¹ C. Richardson,¹ V. Gupta,¹ T. Ahmed, N. Edwards, M. Novak,² J. Peipert,³ A. Waterman, I. Mucsi.
¹Multi-Organ Transplant Program, Department of Surgery, University Health Network, Toronto, ON, Canada; ²Department of Psychiatry, University of Toronto, Toronto, ON, Canada; ³David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
IntroductionKidney transplantation (KT) is the preferred treatment for patients with End-Stage Kidney Disease (ESKD), yet many potentially eligible patients do not act to pursue KT.…
2018 American Transplant Congress
CFZ533, a New Anti-CD40 mAB Demonstrates Comparable Efficacy and Better Renal Function versus Tacrolimus in De-Novo CNI-Free Kidney Transplantation
B. Nashan,¹ H. Tedesco,¹ M. van den Hoogen,¹ S. Berger,¹ D. Cibrik,¹ S. Mulgaonkar,¹ D. Leeser,¹ R. Alloway,¹ A. Patel,¹ J. Pratschke,¹ C. Sommerer,¹ A. Wiseman,¹ A. van Zuilen,¹ U. Laessing,² J. Rush,² B. Haraldsson,² O. Witzke.¹
¹CFZ533 Study Group, Basel, Switzerland; ²Novartis Pharma, Basel, Switzerland.
Purpose: To assess the potential of CFZ533 as primary immunosuppressant in a calcineurin(CNI)-free regimen in de novo kidney transplant (KTx) patients(pts).Method: CFZ533 is a new,…